Orient to Increase Stake in ORIENTBIO by 5.06% to 29.06% via Open Market Purchase
Orient, currently holding a 24.00% stake in ORIENTBIO as a major shareholder, plans to acquire 3 million common shares at 881 KRW each through on-market purchases from August 10 to September 8, 2026. The total transaction amount is approximately 2.64 billion KRW.
Upon completion, Orient's stake will increase by 5.06 percentage points to 29.06%. This purchase is a secondary market acquisition of existing shares, so no new shares are issued and there is no dilution for existing shareholders.
No separate share buyback or dividend disclosure has been made. The increase in Orient's stake may be interpreted as a positive signal for management stability and stock price.
[AI Summary]Orient's open market purchase is executed at market price and does not affect the company's capital structure. The purpose is to strengthen management stability by increasing stake. There is no dilution risk, and the move confirms the major shareholder's financial capability and commitment, likely having a neutral to positive impact on the stock price.
KOSPI Filing Information
Report On Transaction Plan Of Specific Securities By Executives And Major Shareholders